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Abstract Metastasized rectal cancer has long been con-
sidered incurable. During recent years, the treatment of
rectal cancer patients has been improved, and nowadays, a
subgroup of patients might even be cured. The aim of this
study was to investigate the optimal timing of treatment in
a multimodal therapy schedule in order to see whether the
addition of bevacizumab (Avastin) to conventional che-
motherapy was effective. The study included 39 patients
with metastatic rectal cancer between 2009 and 2011, and
three were excluded due to the lack of metastases or lack of
follow-up information. The remaining 36 patients were
divided into groups by treatment intention. The group with
curative intention received mainly oxaliplatin (Eloxatin) in
combination with capecitabine (Xeloda) with or without
bevacizumab (Avastin) for 2 months followed by preop-
erative radiotherapy (RT) and surgery. Palliative patients
had very different treatments depending on their needs of
palliation. The median survival time for patients with
curative intention was 31 months and for the palliative
patients 12 months. Four of the patients (11 %) with
curative intention were considered cured at the end of
follow-up. The response to chemotherapy after 2-month
treatment is a good prognostic sign for which patients can
be cured. Long-lasting palliation can be obtained with this
treatment schedule. The main side effects were gastroin-
testinal events, including bowel perforation, neuropathy,
thrombo-embolic disease and reduced general condition.
All side effects are known, and the treatment is considered
tolerable. We conclude that a good treatment schedule
would be oxaliplatin (Eloxatin) in combination with
capecitabine (Xeloda) with or without bevacizumab (Av-
astin) for 2 months, followed by preoperative RT and
surgery.
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Introduction
Colorectal cancer (CRC) is one of the most common
malignant diseases in the world. In Sweden, there are
around 5,500 new cases each year, where 2,000 of these
cases are rectal cancers. Even though the local recurrence
rate has been reduced for the rectal cancer patients, the
mortality rate is still high, and at the time of diagnosis,
around 25 % of the patients have already developed distant
metastasis. Metastasized rectal cancer has long been con-
sidered incurable, and the treatment has focused on pro-
longing the overall survival and improving the quality of
life [1]. During the recent years, the treatment modalities
have improved by the use of new treatment agents, and
nowadays, a subgroup with metastatic rectal cancer disease
may even be possible to be cured [2].
Most studies investigate CRC as an entity, and rectal
cancer as an own subgroup has only been explored to a
minor extent. The main obstacle for comparing the rectal
cancer group with the colon cancer group is the differences
in the preoperative local treatment. For rectal cancer
patients, preoperative radiotherapy (RT) in combination
with surgery is essential, where colon cancer patients most
commonly are treated with surgery.
The recent years researchers have started to focus on
improving the time schedule between the treatments in
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order to avoid any delays. Multidisciplinary team (MDT)
conferences where oncologists, radiologists, surgeons and
pathologists meet are important tools in the treatment of
CRC patients because it facilitates and coordinates the
examinations and treatments [3]. It also improves the
knowledge of the conference members since doctors with
different modalities can exchange their thoughts.
The aim of this study was to investigate the optimal
timing of treatment in a multimodal therapy schedule in
order to see whether the addition of bevacizumab (Avastin)
to conventional chemotherapy was efficient.
Materials and methods
Inclusion criteria
Patients with metastatic rectal cancer diagnosed between
January 2009 and December 2011 were treated at the
Department of Oncology at the University hospital of
Linko¨ping. The time points (January 2009–December
2011) were chosen since bevacizumab (Avastin) at that
time was included as a neoadjuvant therapy to the con-
ventional chemotherapy.
Descriptive data
Descriptive data such as sex, age, time of diagnosis, date of
surgery and date of diagnosis were obtained from the
Swedish national register for CRC taken from the cancer
centre of the Southeast Swedish Health care region.
Information about chemotherapy and RT, the intention of
the treatment and the side effects were obtained from
medical records.
A total of 39 patients were referred to the MDT con-
ference. Two were excluded due to the lack of metastasis
and one due to the lack of information because treatment
was taking place at another hospital (records were not
available to us). Of the remaining 36 patients, 24 were men
and 12 were women. The median age was 65 years for men
and 67 years for women (range 38–85 years, Table 1).
Twenty-two patients, out of 36, were treated with a
curative intention, while 14 patients were considered pal-
liative (Table 2). The decision of whether the patient was
curable or palliative was made at the MDT conference.
The most common location for metastasis was the liver
(n = 32) followed by regional lymph nodes (n = 28) and
lung metastasis (n = 11, Table 3). The numbers of
metastases in the group of patients with curative and pal-
liative intention are shown in Table 3.
Treatment
The chemotherapy for patients treated with a curative
intention consisted of capecitabine (Xeloda) in combination
with either oxaliplatin (Eloxatin) or irinotecan (Campto)
and, if possible, an addition of bevacizumab (Avastin). The
chemotherapy was followed by preoperative RT and surgery.
The RT in the curative group consisted of short or long
course. The short-course RT was given with 5 Gy in five
fractions during a week, a total of 25 Gy. Surgery was then
performed without any delay. The long-course RT was
given concomitant with capecitabine (Xeloda) with 1.8 Gy
in 28 fractions during 6 weeks, a total of 50.4. Surgery was
then performed about 5 weeks after completion of RT.
Palliative RT is very individual based on the patients’ need
of palliation. We did not find any similar treatment patterns
for the palliative patients; therefore, the RT data for these
patients will not be further discussed.
Patients with low rectal cancers located 0–6 cm from the
anal verge or locally advanced tumours underwent
abdominoperineal excision (APE). Tumours located 6 cm
cranial from the anal verge were treated with total meso-
rectal excision (TME) with anastomoses or Hartmann’s
procedure as appropriate.
Liver surgery was performed at the same time as the
primary rectal cancer surgery (synchronously). Other types
of metastatic surgery were performed either before or after
resection of the primary tumours.
After surgery, the treatment could vary depending on the
outcome of the treatment and some patients received pal-
liative treatment. The palliative chemotherapy consisted of
the same agents as the curative treatment but with an
addition of antibodies against the epidermal growth factor
Table 1 The distribution of gender and age of patients with rectal cancer
Age
Mean Standard deviation Median Minimum Maximum Column N (%)
Gender
Men 65 10 65 38 83 66.7
Women 66 12 67 47 85 33.3
Total 65 10 66 38 85 100.0
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receptor (EGFR) called cetuximab (Erbitux) or pani-
tumumab (Vectibix).
Ethical approval
The study protocol was approved by the ethical committee
in Linko¨ping according to the World Medical Associa-
tion’s Declaration of Helsinki 1964 and the Amendment of
Tokyo in 1975.
Statistics
The v2 test was used to evaluate whether there was a dif-
ference in intention with treatment of men and women as
well as between older and younger patients (70 years of
age or older and \70 years of age). The Kaplan–Meier
method was used to present the differences in overall
survival between curative and palliative patients, between
men and women as well as between older and younger




The overall survival was studied in 36 patients with met-
astatic rectal cancer treated either with curative or with
palliative intention. In all patients, the median survival
time was 17 months. In the group of patients older than
70 years, the median survival was 12 months. Five out of
11 patients were considered possible to be cured from start.
Patients with an age \70 years had a median survival of
20 months where 17 out of 25 patients were considered
possible to be cured (Fig. 1). No significant difference was
found between the number of patients possible to be cured
in the group of patients older than 70 years and the group
of patients younger than 70 years.
Further, the median survival was analysed in men and
women separately. The median survival for men was
18 months where 15 out of 24 patients were considered
possible to be cured with treatment. The women had a
median survival of 11 months where seven out of 12
patients were treated with curative intention (Fig. 2). There
was no significant difference between the number of men
and women possible to cure.
Curative intention
Next, the overall survival for 22 patients with metastatic
rectal cancer treated with curative intention was studied.
The median overall survival in all patients treated with
curative intention was 31 months (Fig. 3).
The majority of patients received chemotherapy as their
first treatment; however, five out of 22 had surgery or RT





Curative intension 15 7 22
Palliative 9 5 14
Total 24 12 36
Table 3 Number (a) and distribution (b) of metastases in rectal cancer patients with curative and palliative intention with treatment
Number of metastasis
1 2 3 or more Total
Count Row N (%) Count Row N (%) Count Row N (%) Count Row N (%)
a
Intention with treatment
Curative intension 4 18.2 8 36.4 10 45.5 22 100.0
Palliative 3 21.4 5 35.7 6 42.9 14 100.0
Total 7 19.4 13 36.1 16 44.4 36 100.0
Liver Lung Lymph nodes Other Total number of patients
b
Intention with treatment
Curative intension 20 7 18 7 22
Palliative 12 4 10 6 14
Total 32 11 28 13 36
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as a first treatment (Fig. 4). The chemotherapy was mainly
oxaliplatin (Eloxatin) in combination with capecitabine
(Xeloda). Eight patients received oxaliplatin (Eloxatin)/
capecitabine (Xeloda). Three of these patients received
short-course RT, and two of them later had surgery. Two
patients who were treated with XELOX received long-
course RT, and one of them later had surgery.
Eight patients received the combination of oxaliplatin
(Eloxatin)/capecitabine (Xeloda) and bevacizumab (Ava-
stin). Out of eight patients, five were treated with short-
course RT and four went on to surgery. One patient who
had XELOX and Avastin received long-course chemora-
diation and later surgery as shown in Fig. 4.
Four patients (11 %) were considered cured at the end of
the study. Two of them received the combination of oxa-
liplatin (Eloxatin)/capecitabine (Xeloda)/bevacizumab
(Avastin) and short-course RT, one patient received oxa-
liplatin (Eloxatin)/capecitabine (Xeloda) in combination
with long-course chemoradiation and one went on to sur-
gery with only preoperative chemotherapy. These four
patients had liver metastases or both liver and lymph node
metastases at the time of diagnosis.
Eleven patients out of 22 underwent liver and rectal
surgery synchronously. Four of the 11 patients later went
on to additional liver surgery.
Palliative intention
Further, the overall survival for the 14 patients with met-
astatic rectal cancer treated with palliative intention was
studied. The median overall survival was 12 months
(Fig. 3). All patients received chemotherapy except for one
(Fig. 5). The first-line palliative treatment was mainly ox-
aliplatin (Eloxatin)/capecitabine (Xeloda); in addition, five
patients received bevacizumab (Avastin). Of the eight
patients who received oxaliplatin (Eloxatin)/capecitabine
(Xeloda), three got second-line treatment (Fig. 5). Of the
five patients with the combination of oxaliplatin (Eloxatin)/
capecitabine (Xeloda)/bevacizumab (Avastin), four had
second-line treatment, two of them received a third line and
one patient received a fourth line of treatment as shown in
Fig. 5.
The type of RT treatment varied a lot between the pal-
liative patients since this treatment is used to shrink
expansive tumours and relief pain. Six out of 14 palliative
patients received RT.
Fig. 1 Kaplan–Meier estimates of cumulative survival in patients
based on age. Median survival time in patients younger than 70 years
was 20 months, and for patients aged 70 years or older, it was
12 months
Fig. 2 Kaplan–Meier estimates of cumulative survival in patients
based on gender. Median survival time for men was 18 months and
for women 11 months
Fig. 3 Kaplan–Meier estimates of cumulative survival in curative
and palliative intention groups. Median overall survival (OS) in
patients with curative and palliative intention was 31 and 12 months,
respectively
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Side effects
Side effects of the treatments that led to a switch of
treatment were found in 16 out of 36 cases (Table 4). The
side effects were neuropathy (two patients, 5.6 %), heart
attack (one patient, 2.8 %), reduced general condition (two
patients, 5.6 %), thrombo-embolic disease (two patients,
5.6 %), gastrointestinal events including diarrhoea (five
patients, 13.9 %) and bowel perforation (one patient,
2.8 %). One patient interrupted treatment due to an infec-
tion (2.8 %). Five patients received cetuximab (Erbitux),
and three of them had an allergic reaction. One of them was
serious and life-threatening.
Discussion
A problem with research of metastasized rectal cancer is
the low number of patients diagnosed with the disease.
Therefore, many studies report CRC as an entity [4, 5].
Rectal cancer as an own subgroup has only been explored
to a minor extent. The main obstacle for comparing the
rectal cancer group with the CRC group is the differences
in the preoperative local treatment. In the treatment of
rectal cancer patients, not only the RT, chemotherapy and
surgery have shown to be of vital importance, but also the
optimal timing between the treatments is important. The
diagnostic tools and treatments are continuously changed
according to new evidence from research. Therefore, it is
necessary for hospitals to collaborate in order to perform
bigger studies and to be able to compare the treatments. In
this study, 39 patients were enrolled where three of the
patients were excluded. The patients were rectal cancer
patients consecutively referred to the surgical department
and received oncological treatment at the University
Fig. 4 Therapy for the curative
intention group. Number of
patients receiving each form of
therapy inside the brackets.
Under each arm the survival of
the patients who had gone
through all the treatments—
chemotherapy, radiotherapy
(RT), and surgery. Some
patients become palliative
during treatment, counting for
the diminishing number in the
flow chart
Fig. 5 Chemotherapy regimens for palliative patients. Number of
patients receiving each form of therapy is shown inside the brackets.
Six of the 14 patients received palliative radiation
Table 4 Side effects for the entire group of the patient material
Side effects Number of patients
Neuropathy 2
Heart attack 1





Allergy to cetuximab 3
life-threatening 1
Dose-altering side effects are not included here. Gastrointestinal
events were mainly diarrhoea, but one of the five patients had the
more severe bowel perforation. Cetuximab was given to five patients,
and three had an allergic reaction severe enough to change treatment
to the fully humanized antibody panitumumab
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hospital of Linko¨ping. All patients were discussed at the
MDT conferences.
In this study, we used a way of dividing the patients into
groups based on their possibility to be cured. If a tumour
regression was found on the computer tomography (CT)
after RT and chemotherapy, the tumours were considered
as possible for surgical resection and the patients were
considered possible to cure. Dividing the patients into
groups based on treatment intention is good since it reflects
the reality in patient care and the results are therefore easier
to apply in clinical work. Also, side effects are more
acceptable if the intention is to cure the patient rather than
to give the patient as much time with a good quality of life
as possible. It is very important to carefully assess the
patient’s chances to be cured before the treatment starts and
also during the treatment so that the clinicians insure that
the patients receive the best treatment. Many patients in the
group with curative intention were later considered palli-
ative, but in this study only their initial clinical status was
counted.
The median overall survival for the whole group of
patients (n = 36) was 17 months, which is in line with the
results found in the MRC FOCUS trial [1]. In that study,
the overall survival was 15–16 months. The differences
between the two studies are that in the MRC FOCUS trial
only the patients with inoperable disease were included,
while in our study, all the patients intended for surgery
were included. Another difference was that in the MRC
FOCUS trial only patients with WHO performance status
0–2 were included, and we included all the cases regardless
of WHO performance status.
In this study, no significant differences were found in
overall survival between patients with curative intention
and the patients with palliative intention the first 6 months.
The reason for these results might be that during this period
most patients are still alive regardless what treatment they
have received. After 6 months, a significant difference was
found in overall survival between the patients with curative
intention and the patients with palliative intention. After
around 28 months, the differences in survival between the
two groups disappear. Taken together, the results suggest
that the patients can live a long time with their disease even
though the tumour cannot be removed surgically.
We also showed that 22 out of 36 patients were treated
with curative intention, which is the high number of
patients compared to how this group of patients was treated
10 years ago. Ten years ago, almost all the patients were
considered palliative. It would be interesting in the future
to further study which patient would benefit from a more
aggressive treatment.
Few studies have analysed the relationship between the
treatment with oxaliplatin (Eloxatin)/capecitabine (Xeloda)
and bevacizumab (Avastin) in metastatic CRC and overall
survival [6, 7]. In this study, we found a median overall
survival of 31 months in 22 patients with curative intention
treated with the combination of oxaliplatin (Eloxatin)/
capecitabine (Xeloda) and, if possible, bevacizumab (Av-
astin). In another study by Diaz-Rubio et al. [8] on patients
with metastatic CRC treated with oxaliplatin (Eloxatin)/
capecitabine (Xeloda) and bevacizumab (Avastin), a
median survival time of 23.2 months was found. This result
shows that more research in this field is necessary in order
to improve the preoperative treatment and the patients’
survival.
Our results indicate that 2 months of neoadjuvant che-
motherapy followed by RT and then surgery is a feasible
treatment. With this approach, one does not risk that the
rectum leaves untreated, it is good for both curative and
palliative patients, and one has time to perform liver sur-
gery first, if it is clinically indicated.
Side effects are usually described using common ter-
minology criteria of adverse events (CTCAE) from the US
department of Health and Human Services [9]. It is a list of
common side effects of treatments graded on a scale of 1–5
where one is mild and five is an adverse effect causing
death. Many publications, for example, the MRC FOCUS
trial, use grade three or four adverse effects to describe
their side effects [1]. This was not possible in our study
because of insufficient documentation of the severity of
side effects in the medical records. Therefore, we used the
switch from one chemotherapy regimen to another as a
measurement of severe side effects. It was both the doctor’s
and the patient’s decisions to end the treatment. Diarrhoea,
neuropathy and reduced general condition are well-known
side effects to oxaliplatin (Eloxatin)/capecitabine (Xeloda)
treatment. Known side effects to bevacizumab (Avastin)
include bowel perforation and thrombo-embolic disease. In
our study, one bowel perforation was found in patients
treated with bevacizumab (Avastin) and two patients suf-
fered from thrombo-embolic disease. Our results show that
the risk of side effects by bevacizumab (Avastin) is slightly
higher than reported by others. Tebbutt et al. [10] showed
that thrombo-embolic events occurred in one of 27 patients
(4 %) treated with bevacizumab (Avastin). This difference
can be due to a small number of patients in our study or due
to the difference in how the adverse events were deter-
mined. Although our incidence of side effects is higher
than that in other studies, we consider this treatment well
tolerable. In the group of patient with palliative intention,
cetuximab (Erbitux) was used. One common side effect of
cetuximab (Erbitux) treatment is allergic reactions. In this
study, we found that three out of five patients with cetux-
imab (Erbitux) treatment had an allergic reaction to the
treatment, and one of the patients even had a life-threat-
ening allergic reaction. This result shows that more than
half of the patients receive allergic reaction due to
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cetuximab (Erbitux) treatment. Although the number of
patients is small, we consider this evidence as serious,
which must be investigated further.
Conclusion
We consider the treatment with oxaliplatin (Eloxatin)/
capecitabine (Xeloda) in combination with bevacizumab
(Avastin) followed by RT as a well-tolerable and good
preoperative treatment in patients with metastatic rectal
cancer. Eleven per cent of the patients with metastatic
disease can be cured by neoadjuvant chemotherapy, RT
and surgery. The response to chemotherapy after 2-month
treatment is a good prognostic sign for which patients can
be cured. Long-lasting palliation can also be obtained with
this treatment schedule; however, surgery is not indicated
for the palliative patient.
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